Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: A pooled analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 4, 2015, Pages 683-689

  Lang Kuhs, Krystle A ^a   Anantharaman, Devasena ^b   Waterboer, Tim ^c   Johansson, Mattias ^b   Brennan, Paul ^b   Michel, Angelika ^c   Willhauck Fleckenstein, Martina ^c   Purdue, Mark P ^a,d   Holcátová, Ivana ^e   Ahrens, Wolfgang ^f   Lagiou, Pagona ^g   Polesel, Jerry ^h   Simonato, Lorenzo ⁱ   Merletti, Franco ^j   Healy, Claire M ^k   Kjaerheim, Kristina ^l   Conway, David I ^m   Macfarlane, Tatiana V ⁿ   Thomson, Peter ^o   Castellsagué, Xavier ^p   Znaor, Ariana ^b,q   Black, Amanda ^a   Huang, Wen Yi ^a   Krogh, Vittorio ^r   Trichopoulou, Antonia ^g,s,t   Bueno De Mesquita, H B A S ^u,v,w,x   Clavel Chapelon, Françoise ^y,z,aa   Weiderpass, Elisabete ^l,ab,ac,ad   Ekström, Johanna ^ae   Riboli, Elio ^w   Tjønneland, Anne ^af   Sánchez, María José ^ag,ah   Travis, Ruth C ^ai   Hildesheim, Allan ^a   Pawlita, Michael ^c   Kreimer, Aimée R ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e CHARLES UNIVERSITY   (Czech Republic)

^f LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k TRINITY COLLEGE DUBLIN   (Ireland)

^l CANCER REGISTRY OF NORWAY   (Norway)

^m UNIVERSITY OF GLASGOW   (United Kingdom)

ⁿ UNIVERSITY OF ABERDEEN   (United Kingdom)

^o University of Newcastle on Tyne   (United Kingdom)

^p HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^q CROATIAN NATIONAL INSTITUTE OF PUBLIC HEALTH   (Croatia)

^r NATIONAL CANCER INSTITUTE   (Italy)

^s HELLENIC HEALTH FOUNDATION   (Greece)

^t BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^u NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^v UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^w IMPERIAL COLLEGE LONDON   (United Kingdom)

^x UNIVERSITY OF MALAYA   (Malaysia)

^y CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^z UNIVERSITÉ PARIS SACLAY   (France)

^aa INSTITUT GUSTAVE ROUSSY   (France)

^ab UNIVERSITY OF TROMSØ   (Norway)

^ac KAROLINSKA INSTITUTE   (Sweden)

^ad FOLKHÄLSAN RESEARCH CENTER   (Finland)

^ae LUND UNIVERSITY   (Sweden)

^af DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^ag UNIVERSITY OF GRANADA   (Spain)

^ah CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^ai UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; HUMAN PAPILLOMAVIRUS TYPE 16 E6 ANTIBODY; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS ANTIBODY; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; RISK FACTORS; YOUNG ADULT;

EID: 84925848405     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1217     Document Type: Article

References (35)

1. Hocking JS, Stein A, Conway EL, Regan D, Grulich A, Law M, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011; 104:886-91.
2. Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 2011;129:733-41.
3. Reddy VM, Cundall-Curry D, Bridger MW. Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl 2010;92:655-9.
4. Syrjanen S. HPV infections and tonsillar carcinoma. J Clin Pathol 2004; 57:449-55.
5. Ioka A, Tsukuma H, Ajiki W, Oshima A. Trends in head and neck cancer incidence in Japan during 1965-1999. Jpn J Clin Oncol 2005;35:45-7.
6. Braakhuis BJ, Visser O, Leemans CR. Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol 2009;45:e85-9.
7. Chaturvedi AK, Engels EA, AndersonWF, Gillison ML. Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.
8. Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012;30(Suppl 5): F34-54.
9. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013;31:4550-9.
10. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301.
11. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75.
12. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
13. Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362-6.
14. Hong AM, Grulich AE, Jones D, Lee CS, Garland SM, Dobbins TA, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010;28:3269-72.
15. Kreimer AR, Chaturvedi AK. HPV-associated oropharyngeal cancers-are they preventable? Cancer Prev Res 2011;4:1346-9.
16. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-83.
17. Zumbach K, Hoffmann M, Kahn T, Bosch F, Gottschlich S, Gorogh T, et al. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer 2000;85:815-8.
18. Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP, et al. Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer 2007;120:825-32.
19. Dahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dillon L, El-Naggar AK, et al. Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. Clin Cancer Res 2003;9:2620-6.
20. Furniss CS, McClean MD, Smith JF, Bryan J, Nelson HH, Peters ES, et al. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 2007;120:2386-92.
21. Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP, et al. Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol 2008;44:242-50.
22. Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J, et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007;99:1801-10.
23. Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, et al. Human papillomavirus infections and upper aerodigestive tract cancers: the ARCAGE study. J Natl Cancer Inst 2013;105: 536-45.
24. Ribeiro KB, Levi JE, Pawlita M, Koifman S, Matos E, Eluf-Neto J, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol 2011;40:489-502.
25. Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013;31:2708-15.
26. Kreimer AR, Brennan P, Lang Kuhs KA, Waterboer T, Clifford G, Franceschi S, et al. Human papillomavirus antibodies and future risk of anogenital cancer: an nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. J Clin Oncol. In Press.
27. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
28. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:273S-309S.
29. Lagiou P, Georgila C, Minaki P, Ahrens W, Pohlabeln H, Benhamou S, et al. Alcohol-related cancers and genetic susceptibility in Europe: the ARCAGE project: study samples and data collection. Eur J Cancer Prev 2009;18: 76-84.
30. Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006;309:200-4.
31. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, et al. Multiplex human papillomavirus serology based on in situpurified glutathione s-transferase fusion proteins. Clin Chem 2005;51: 1845-53.
32. Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, et al. Inter-SCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst 2012;104:147-58.
33. Combes JD, Pawlita M, Waterboer T, Hammouda D, Rajkumar T, Vanhems P, et al. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. Int J Cancer 2014;135: 2453-61.
34. Muller M, Viscidi RP, Sun Y, Guerrero E, Hill PM, Shah F, et al. Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology 1992;187:508-14.
35. Holzinger D, Baboci L, Wichmann G, Michel A, Hofler D, Schmitt M, et al. Sensitivity of antibodies against HPV16 E6 and other early proteins for detection of HPV16-driven head and neck cancer. In: 29th International Human Papillomavirus Conference 2014; August 21-25; Seattle Washington.